share_log

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $6

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $6

HC Wainwright & Co.维持对Prelude Therapeutics的买入,将目标价下调至6美元
Benzinga ·  2023/10/19 07:06

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and lowers the price target from $17 to $6.

HC Wainwright&Co.分析师罗伯特·伯恩斯维持Prelude Treateutics(纳斯达克:PRLD)的买入,并将目标价从17美元下调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发